Synageva BioPharma Announces $80 Million Proposed Public Offering of Common Stock
Synageva BioPharma Corp. (“Synageva”) (NASDAQ: GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced that it has commenced a $80 million underwritten public offering of shares of its common stock. In connection with this offering, Synageva expects to grant to the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any, equal to up to 15% of the number of shares of common stock sold in the offering. Morgan Stanley and J.P. Morgan are acting as joint book-running managers in the offering.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.